ALPN Alpine Immune Sciences

Nivalis Therapeutics Inc a pharmaceutical company, focuses on the discovery and development of product candidates for patients with cystic fibrosis. Geographically operation of the group is functioned through United States.

$8.30  +0.02 (0.24%)
As of 02/02/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/17/2015
Outstanding shares:  30,400,679
Average volume:  86,393
Market cap:   $251,717,622
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYX38M1

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%